ポリ（ADPリボース）ポリメラーゼ（PARP）阻害剤の世界市場レポート 2025年

ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の市場規模は、今後数年間で急成長が見込まれます。2029年にはCAGR15.5%で134億5,000万米ドルに成長します。予測期間中の成長は、医薬品の生産と供給の増加、BRCA変異がんの有病率の上昇、乳がん罹患率の増加、モノクローナル抗体の使用拡大、ヘルスケア支出の増加などの要因によるものと考えられます。予測期間における主要動向としては、バイオマーカー研究の進展、併用療法の利用、薬剤開発における人工知能の統合、バイオマーカー主導型療法の進展、次世代PARP阻害剤の開発などが挙げられます。

乳がんの有病率の増加は、ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤市場の成長を促進すると予想されます。乳がんは、乳房細胞が制御不能に増殖して悪性腫瘍を形成し、身体の他の部位に転移する疾患です。有病率上昇の要因としては、人口の高齢化、ライフスタイルの変化、遺伝的要因、ホルモンバランスの乱れ、肥満、飲酒、環境リスクへの暴露などが挙げられます。PARP阻害剤は、PARP酵素ががん細胞のDNA損傷を修復する能力を阻害することによって乳がん患者を助け、特にBRCA1またはBRCA2変異を有する腫瘍において細胞死を引き起こします。全米乳がん財団によると、2025年1月、米国では女性の8人に1人が生涯に乳がんと診断されます。2024年には、女性31万720人、男性2,800人が浸潤性乳がんと診断されました。その結果、乳がんの有病率の増加がPARP阻害剤市場の成長に拍車をかけています。

PARP阻害剤市場の企業は、一部のがんに見られる特定の遺伝子変異を標的とした抗がん剤などのがん治療の進展に注力しています。これらの医薬品は、細胞分裂の阻害、腫瘍の増殖に必要なタンパク質の阻害、がんと闘うための免疫系の刺激など、さまざまなメカニズムを通じて、がん細胞の増殖を抑制したり、転移を防いだり、破壊したりすることで効果を発揮します。例えば、2024年3月、インドの製薬会社ザイダス・ライフサイエンシズ社は、PARP阻害剤オラパリブのジェネリック医薬品であるIBYRAを発売しました。この医薬品は、HRD陽性とBRCA陽性のがん患者に対して、手頃な価格で的を絞った治療選択肢を提供し、先発医薬品に比べて治療費を大幅に削減します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤に関する世界PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因要因）
• 最終用途産業の分析
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場の成長率分析
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の市場規模実績と成長、2019～2024年
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場規模と成長予測、2024～2029年、2034年
• 世界のポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の有効市場規模（TAM）

第6章 市場セグメンテーション

• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場（タイプ別）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オラパリブ
• ルカパリブ
• ニラパリブ
• タラゾパリブ
• その他
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場（適応症別）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 卵巣がん
• 乳がん
• 前立腺がん
• 膵臓がん
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場（流通チャネル別）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場（エンドユーザー別）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 研究機関
• その他
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場、オラパリブのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• BRCA変異がん
• HRD陽性がん
• 維持療法
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場、ルカパリブのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 卵巣がん
• 前立腺がん
• 膵臓がん
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場、ニラパリブのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 第一選択治療
• 再発がん治療
• 末期がん
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場、タラゾパリブのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 乳がん
• 生殖細胞系BRCA変異腫瘍
• 術前療法または術後療法
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 新規PARP阻害剤
• 治験薬
• 新規組み合わせ

第7章 地域別・国別分析

• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場（地域別）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤の世界市場（国別）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤市場の競合情勢
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤市場における企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • AbbVie Inc.
  • Merck & Co. Inc.
  • Bayer AG

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Bristol-Myers Squibb Company
• GSK plc
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim
• Vertex Pharmaceuticals Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• BeiGene LTD
• Karyopharm Therapeutics Inc.
• Clovis Oncology Inc.
• Repare Therapeutics Inc.
• Ribon Therapeutics
• Artios Pharma
• IMPACT Therapeutics Inc.
• BiPar Sciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 2029年のポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤市場-最も新たな機会を提供する国
• 2029年のポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤市場-最も新たな機会を提供するセグメント
• ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤市場：、2029年-成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

PARP inhibitors (poly(ADP-ribose) polymerase inhibitors) are a class of drugs primarily used in cancer treatment. These medications work by inhibiting DNA repair in cancer cells, especially in cancers with BRCA mutations. They are commonly prescribed for ovarian and breast cancers and are typically taken orally. PARP inhibitors help lower the risk of cancer recurrence after chemotherapy, though they may cause side effects such as fatigue and low blood cell counts.

The main types of PARP inhibitors include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib is a well-known PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers by blocking DNA repair in cancer cells, which leads to cell death. These drugs are used for various indications, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. They are distributed via hospital pharmacies, retail pharmacies, and online platforms, and are utilized by hospitals, specialty clinics, research institutions, and other healthcare settings.

The poly (ADP-Ribose) polymerase (PARP) inhibitors market research report is one of a series of new reports from The Business Research Company that provides poly (ADP-Ribose) polymerase (PARP) inhibitors market statistics, including the poly (ADP-Ribose) polymerase (PARP) inhibitors industry global market size, regional shares, competitors with the poly (ADP-Ribose) polymerase (PARP) inhibitors market share, detailed poly (ADP-Ribose) polymerase (PARP) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the poly (ADP-Ribose) polymerase (PARP) inhibitors industry. This poly (ADP-Ribose) polymerase (PARP) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The poly(ADP-ribose) polymerase (PARP) inhibitors market size has grown rapidly in recent years. It will grow from $6.53 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth during the historic period can be attributed to factors such as the rising incidence of cancer, increased genetic testing, higher success rates in clinical trials, expanding insurance coverage, and growth in cancer research.

The poly(ADP-ribose) polymerase (PARP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $13.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth during the forecast period can be attributed to factors such as the increasing production and supply of drugs, the rising prevalence of BRCA-mutated cancers, the growing incidence of breast cancer, the expanding use of monoclonal antibodies, and rising healthcare expenditure. Key trends in the forecast period include advancements in biomarker research, the use of combination therapies, the integration of artificial intelligence in drug development, progress in biomarker-driven therapies, and the development of next-generation PARP inhibitors.

The increasing prevalence of breast cancer is expected to drive the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market. Breast cancer is a disease where breast cells grow uncontrollably, forming malignant tumors that can spread to other areas of the body. Factors contributing to the rising prevalence include aging populations, lifestyle changes, genetic factors, hormonal imbalances, obesity, alcohol consumption, and exposure to environmental risks. PARP inhibitors help breast cancer patients by blocking the PARP enzyme's ability to repair DNA damage in cancer cells, causing cell death, particularly in tumors with BRCA1 or BRCA2 mutations. According to the National Breast Cancer Foundation, in January 2025, one in eight women in the United States will be diagnosed with breast cancer in their lifetime. In 2024, 310,720 women and 2,800 men were diagnosed with invasive breast cancer. As a result, the increasing prevalence of breast cancer is fueling the growth of the PARP inhibitors market.

Companies in the PARP inhibitors market are focused on advancing cancer treatments, such as anticancer medications, to target specific genetic mutations found in some cancers. These medicines work by inhibiting the growth of cancer cells, preventing their spread, or destroying them through various mechanisms, such as interfering with cell division, blocking proteins necessary for tumor growth, or stimulating the immune system to combat cancer. For instance, in March 2024, Zydus Lifesciences Limited, a pharmaceutical company based in India, launched IBYRA, a generic version of the PARP inhibitor olaparib. This drug offers an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers, significantly reducing treatment costs compared to the original medication.

In June 2023, Ariceum Therapeutics GmbH, a biotechnology company based in Germany, acquired Theragnostics Ltd. for an undisclosed amount. This acquisition aims to expand Ariceum Therapeutics' radiopharmaceutical pipeline by incorporating Theragnostics' next-generation PARP inhibitor radiation therapies, while also strengthening its U.S. operations. Theragnostics Ltd, a U.K.-based biopharmaceutical company, specializes in developing radio-labeled PARP inhibitors.

Major players in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., and Allarity Therapeutics Inc.

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in poly(ADP-ribose) polymerase (PARP) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The poly(ADP-ribose) polymerase (PARP) inhibitors market consists of sales of rubraca, zejula, and talzenna. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on poly(adp-ribose) polymerase (parp) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for poly(adp-ribose) polymerase (parp) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The poly(adp-ribose) polymerase (parp) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
• 2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users
• Subsegments:
• 1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
• 2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
• 3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
• 4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
• 5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Characteristics

3. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends And Strategies

4. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth Rate Analysis
• 5.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Total Addressable Market (TAM)

6. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segmentation

• 6.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Olaparib
• Rucaparib
• Niraparib
• Talazoparib
• Other Types
• 6.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer
• 6.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutions
• Other End-Users
• 6.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BRCA-Mutated Cancers
• HRD-Positive Cancers
• Maintenance Therapy
• 6.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ovarian Cancer
• Prostate Cancer
• Pancreatic Cancer
• 6.7. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Line Treatment
• Recurrent Cancer Treatment
• Late-Stage Cancer
• 6.8. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Germline BRCA-Mutated Tumors
• Neoadjuvant Or Adjuvant Therapy
• 6.9. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Emerging PARP Inhibitors
• Investigational Therapies
• Novel Combinations

7. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Regional And Country Analysis

• 7.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 8.1. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 9.1. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 9.2. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 10.1. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 11.1. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 11.2. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 12.1. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 13.1. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 14.1. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 14.2. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 15.1. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 15.2. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 16.1. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 17.1. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 18.1. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 19.1. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 20.1. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 21.1. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 21.2. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 22.1. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 23.1. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 23.2. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 24.1. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 24.2. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 25.1. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 25.2. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 26.1. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 26.2. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 27.1. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 28.1. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 28.2. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 29.1. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
• 29.2. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape
• 30.2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Bristol-Myers Squibb Company
• 31.3. GSK plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Boehringer Ingelheim
• 31.6. Vertex Pharmaceuticals Inc.
• 31.7. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• 31.8. BeiGene LTD
• 31.9. Karyopharm Therapeutics Inc.
• 31.10. Clovis Oncology Inc.
• 31.11. Repare Therapeutics Inc.
• 31.12. Ribon Therapeutics
• 31.13. Artios Pharma
• 31.14. IMPACT Therapeutics Inc.
• 31.15. BiPar Sciences Inc.

32. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

34. Recent Developments In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

35. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer